Results overview: Found 2 records in 0.02 seconds.
Articles, 2 records found
Articles 2 records found  
1.
11 p, 693.2 KB ERIC recommendations for TP53 mutation analysis in chronic lymphocytic leukemia-update on methodological approaches and results interpretation / Malcikova, J. (Brno, Czech Republic) ; Tausch, E. (Ulm, Germany) ; Rossi, D. (Bellinzona, Switzerland) ; Sutton, L. A. (Stockholm, Sweden) ; Soussi, T. (Stockholm, Sweden) ; Zenz, T. (Zürich, Switzerland) ; Kater, A. P. (Amsterdam, The Netherlands) ; Niemann, C. U. (Copenhagen, Denmark) ; González De Castro, David (Belfast, UK) ; Davi, F. (Paris, France) ; Gonzalez Diaz, M. (Salamanca, Spain) ; Moreno, Carol (Institut d'Investigació Biomèdica Sant Pau) ; Gaidano, G. (Novara, Italy) ; Stamatopoulos, K. (Thessaloniki, Greece) ; Rosenquist, R. (Stockholm, Sweden) ; Stilgenbauer, S. (Ulm, Germany) ; Ghia, P. (Milan, Italy) ; Pospisilova, S. (Brno, Czech Republic) ; Universitat Autònoma de Barcelona
In chronic lymphocytic leukemia (CLL), TP53 gene defects, due to deletion of the 17p13 locus and/or mutation(s) within the TP53 gene, are associated with resistance to chemoimmunotherapy and a particularly dismal clinical outcome. [...]
2018 - 10.1038/s41375-017-0007-7
Leukemia, Vol. 32 (february 2018) , p. 1070-1080  
2.
9 p, 809.0 KB Karyotypic complexity rather than chromosome 8 abnormalities aggravates the outcome of chronic lymphocytic leukemia patients with TP53 aberrations / Blanco, Gonzalo (Department of Experimental and Health Sciences, Universitat Pompeu Fabra, Barcelona, Spain) ; Puiggros, Anna (Institut Hospital del Mar d'Investigacions Mèdiques) ; Baliakas, Panagiotis (Department of Immunology, Genetics and Pathology, Science for Life Laboratory, Uppsala University, Uppsala, Sweden) ; Athanasiadou, Anastasia (Hematology Department and HCT Unit, G. Papanicolaou Hospital, Thessaloniki, Greece) ; García-Malo, MªDolores (Servicio de Hematología, Hospital Universitario Morales Meseguer, Murcia, Spain) ; Collado, Rosa (Servicio de Hematología, Consorcio Hospital General Universitario, Valencia, Spain) ; Xochelli, Aliki (Institute of Applied Biosciences, CERTH, Thessaloniki, Greece) ; Rodríguez-Rivera, María (Institut Hospital del Mar d'Investigacions Mèdiques) ; Ortega, Margarita (Hospital Universitari Vall d'Hebron) ; Calasanz, Mª José (Servicio de Citogenética, Departamento de Genética, Universidad de Navarra, Pamplona, Spain) ; Luño, Elisa (Servicio de Hematología, Hospital Universitario Central de Asturias, Oviedo, Spain) ; Vargas, MªTeresa (UGC de Hematología, Hospital Universitario Virgen del Rocío, Instituto de Biomedicina de Sevilla (IBIS), Sevilla, Spain) ; Grau, Javier (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Martínez-Laperche, Carolina (Laboratorio de Genética Hematológica, Servicio de Hematología, Hospital G.U. Gregorio Marañón, Instituto de Investigación Sanitaria Gregorio Marañón, Madrid, Spain) ; Valiente, Alberto (Servicios de Genética y Hematología, Complejo Hospitalario de Navarra, Pamplona, Spain) ; Cervera, José (Unidad de Genética, Hospital Universitario La Fe, Valencia, Spain) ; Anagnostopoulos, Achilles (Hematology Department and HCT Unit, G. Papanicolaou Hospital, Thessaloniki, Greece) ; Gimeno, Eva (Servei d'Hematologia, Hospital del Mar, Barcelona, Spain) ; Abella Monreal, Eugenia (Servei d'Hematologia, Hospital del Mar, Barcelona, Spain) ; Stalika, Evangelia (Institute of Applied Biosciences, CERTH, Thessaloniki, Greece) ; Hernández Rivas, Jesús María (Hospital Universitario de Salamanca) ; Ortuño, Francisco José (Servicio de Hematología, Hospital Universitario Morales Meseguer, Murcia, Spain) ; Robles, Diego (Servicio de Hematología, Hospital Txagorritxu, Vitoria, Spain) ; Ferrer, Ana (Institut Hospital del Mar d'Investigacions Mèdiques) ; Ivars, David (Servicio de Hematología, Consorcio Hospital General Universitario, Valencia, Spain) ; González, Marcos (Servicio de Hematología, Hospital Universitario de Salamanca, IBSAL, IBMCC, Centro de Investigación del Cáncer, Universidad de Salamanca, CSIC, Salamanca, Spain) ; Bosch, Francesc (Hospital Universitari Vall d'Hebron) ; Abrisqueta, Pau (Hospital Universitari Vall d'Hebron) ; Stamatopoulos, Kostas (Institute of Applied Biosciences, CERTH, Thessaloniki, Greece) ; Espinet, Blanca (Institut Hospital del Mar d'Investigacions Mèdiques) ; Universitat Autònoma de Barcelona
Patients with chronic lymphocytic leukemia (CLL) harboring TP53 aberrations (TP53 abs; chromosome 17p deletion and/or TP53 mutation) exhibit an unfavorable clinical outcome. Chromosome 8 abnormalities, namely losses of 8p (8p−) and gains of 8q (8q+) have been suggested to aggravate the outcome of patients with TP53 abs. [...]
2016 - 10.18632/oncotarget.13106
Oncotarget, Vol. 7 (november 2016) , p. 80916-80924  

See also: similar author names
1 Stamatopoulos, K
1 Stamatopoulos, Kostas
Interested in being notified about new results for this query?
Set up a personal email alert or subscribe to the RSS feed.